BENZOTHIAZOLE COMPOUND AND MEDICINE CONTAINING SAME
|Posted date||Mar 13, 2017|
|International application number||2015JP070317|
|International publication number||WO 2016010092|
|Date of international filing||Jul 15, 2015|
|Date of international publication||Jan 21, 2016|
|Title||BENZOTHIAZOLE COMPOUND AND MEDICINE CONTAINING SAME|
|Abstract||Provided are: a compound that is useful as an amyloid oxidation catalyst which can be applied inside a living body and can be applied not only to Aβ peptides but also to other amyloids; and an amyloid-related preventive or therapeutic drug using said compound. A benzothiazole compound which is represented by general formula (1) (in the formula, X represents a halogen atom; R1 represents a hydrocarbon group which may have a substituent; R2 represents a hydrogen atom or a hydrocarbon group which may have a substituent; R3 and R4 are the same or different and represent a hydrogen atom, an alkoxy group, a halogen atom, an amino group, a nitro group, a cyano group, or a hydrocarbon group which may have a substituent; R2 and R4 together may form an alkylene group, and R5 represents an anion).|
|Outline of related art and contending technology||
Usually, by folding of the protein, to form a specific native are responsible for vital functions, on the other hand misfolding rich fibers can be aggregated into β-sheet structure (amyloid-) sometimes. In the course of the production of the amyloid aggregates (oligomers, proto-fibrillar, fibers) known to cause various functions and disorders, (such conditions include 'amyloid' collectively referred to as a) one or more 20 of the amyloid protein have been identified as the causative agent of. Amyloid such as, for example, β amyloid Alzheimer's disease, tau protein, Parkinson's disease α-synuclein, amylin diabetes, systemic - cis transthyretin, such as Huntington's disease Huntingtin is known.
These pathogenic amyloid development of therapeutics targeting strategy include, for example Alzheimer's disease amyloid amyloid β (hereinafter referred to as A β) for, producing A β precursor protein from the enzyme inhibitor, accelerator A β-degrading enzyme, immunotherapy, and the like of the aggregation-inhibiting A β known. On the other hand, with respect to A β, oxidant Met A β peptide (A β peptide Met residues of the sulfur atom is oxidized with an oxidant (O) ) a small amount remains within the living body, and the agglomerates as compared to an oxidant may be Met A β peptide has been reported to have low (non-patent document 1-3). From such a viewpoint, the present inventors, represented by the formula flavin binding site A β photocatalyst A β A β peptide using the oxidation of a peptide in which the oxidant is obtained, the oxidant may be A β A β peptide reported to suppress the flocculation of (non-patent document 4).
|IPC(International Patent Classification)||
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
|Reference ( R and D project )||ERATO KANAI Life Science Catalysis AREA|
Contact Information for " BENZOTHIAZOLE COMPOUND AND MEDICINE CONTAINING SAME "
- Japan Science and Technology Agency Department of Intellectual Property Management
- URL: http://www.jst.go.jp/chizai/
- Address: 5-3, Yonbancho, Chiyoda-ku, Tokyo, Japan , 102-8666
- Fax: 81-3-5214-8476